Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Travere Therapeutics Inc (NASDAQ: TVTX) closed at $35.41 in the last session, down -2.34% from day before closing price of $36.26. In other words, the price has decreased by -$2.34 from its previous closing price. On the day, 0.76 million shares were traded. TVTX stock price reached its highest trading level at $37.5 during the session, while it also had its lowest trading level at $35.31.
Ratios:
We take a closer look at TVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 4.48 whereas as Long-Term Debt/Eq ratio is at 4.40.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on October 31, 2025, Reiterated its Buy rating but revised its target price to $48 from $34 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 04 ’25 when Calvin Sandra sold 67,115 shares for $36.00 per share. The transaction valued at 2,416,140 led to the insider holds 48,545 shares of the business.
SANDRA CALVIN bought 67,115 shares of TVTX for $2,416,140 on Nov 04 ’25. On Oct 31 ’25, another insider, Coughlin Timothy, who serves as the Director of the company, sold 18,000 shares for $35.03 each. As a result, the insider received 630,601 and left with 55,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 3168215040 and an Enterprise Value of 3243433984. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.27 while its Price-to-Book (P/B) ratio in mrq is 43.06. Its current Enterprise Value per Revenue stands at 7.442 whereas that against EBITDA is -92.582.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.89, which has changed by 0.8094021 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $36.87, while it has fallen to a 52-week low of $12.91. The 50-Day Moving Average of the stock is 18.80%, while the 200-Day Moving Average is calculated to be 69.37%.
Shares Statistics:
According to the various share statistics, TVTX traded on average about 2.24M shares per day over the past 3-months and 1315710 shares per day over the past 10 days. A total of 89.46M shares are outstanding, with a floating share count of 87.73M. Insiders hold about 1.95% of the company’s shares, while institutions hold 115.96% stake in the company. Shares short for TVTX as of 1763078400 were 10355808 with a Short Ratio of 4.63, compared to 1760486400 on 11840340. Therefore, it implies a Short% of Shares Outstanding of 10355808 and a Short% of Float of 11.66.
Earnings Estimates
The performance of Travere Therapeutics Inc (TVTX) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.07, with high estimates of $0.23 and low estimates of -$0.07.
Analysts are recommending an EPS of between $1.06 and $0.53 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is $1.82, with 7.0 analysts recommending between $2.98 and $0.73.
Revenue Estimates
According to 13 analysts, . The current quarter’s revenue is expected to be $143.04M. It ranges from a high estimate of $184M to a low estimate of $122.37M. As of . The current estimate, Travere Therapeutics Inc’s year-ago sales were $74.79MFor the next quarter, 13 analysts are estimating revenue of $133.51M. There is a high estimate of $144.7M for the next quarter, whereas the lowest estimate is $119.57M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $545M, while the lowest revenue estimate was $483.41M, resulting in an average revenue estimate of $503.75M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $691.8M in the next fiscal year. The high estimate is $802.8M and the low estimate is $580M.
